Anterogen.Co.,Ltd.
065660.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$138.28B
Close$
$-6904.84
150% downside
Current Fair Value
150% downsideOvervalued by 150% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $138.28 Billion |
|---|---|
| Enterprise Value | $136.62 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-110.37 |
| Beta | 0.12 |
| Outstanding Shares | 10,006,100 |
Return
| Return on Equity | -2.01% |
|---|---|
| Return on Assets | -1.96% |
| Return on Invested Capital | -3.05% |
Valuation & Multiples
| P/E Ratio | -85.57 |
|---|---|
| PEG | -129.06 |
| Price to Sales | 16.53 |
| Price to Book Ratio | 1.72 |
| Enterprise Value to Revenue | 16.32 |
| Enterprise Value to EBIT | -55.52 |
| Enterprise Value to Net Income | -85 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Anterogen.Co.,Ltd.
32 employees
CEO: Seong-Gu Lee Anterogen.Co.,Ltd., a South Korean bio-venture founded in 2000 and headquartered in Seoul, specializes in the global research, development, and commercialization of therapeutic products utilizing adipose-derived stem cells. Their pharmac...